IDYA Ideaya Biosciences announces ide892, a potential best-in-class mta-cooperative prmt5 inhibitor, initiates part 2 monotherapy expansion
IDYA Ideaya Biosciences announces ide892, a potential best-in-class mta-cooperative prmt5 inhibitor, initiates part 2 monotherapy expansion in the phase 1/2 study in mtap-deleted pancreatic and lung cancers
Story updates
10:39:37 AM UTC
SquawkNews
IDYA - Ideaya Biosciences announces ide892, a potential best-in-class mta-cooperative prmt5 inhibitor, initiates part 2 monotherapy expansion in the phase 1/2 study in mtap-deleted pancreatic and lung cancers
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.